In RET fusion-positive NSCLC, SY-5007 achieved an ORR of 71.4% in treatment-naïve patients and 58.3% in previously treated patients at RP2D, which were comparable to those reported for pralsetinib and selpercatinib. Here, RET is linked to non-small cell lung carcinoma.